Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

96.84
+0.53000.55%
Volume:137.83K
Turnover:13.31M
Market Cap:6.29B
PE:-6.88
High:97.35
Open:96.31
Low:95.49
Close:96.31
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:0.36
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-603.34
PE(LYR):-206.04

Loading ...

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

TIPRANKS
·
Jun 15

Mirum, Incyte report pivotal Phase 2 PROGRESS data showing zilurgisertib cuts new FOP bone lesion volume 99.9% at Week 24

Reuters
·
Jun 15

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results From Progress Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Jun 15

Mirum grants inducement equity awards to 8 new hires, sets options at $94 per share

Reuters
·
Jun 12

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 12

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 11

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley

TIPRANKS
·
Jun 11

Mirum CFO Eric Bjerkholt disposes of common shares worth $468,720.88

Reuters
·
Jun 10

Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference

MT Newswires Live
·
Jun 04

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

TIPRANKS
·
Jun 04

Mirum CEO Christopher Peetz disposes of USD 2.88 million in common shares

Reuters
·
Jun 03

Mirum Pharma director Saira Ramasastry disposes of 3,977 common shares for $397,700

Reuters
·
Jun 03

Mirum Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Jun 02

Mirum Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $145

THOMSON REUTERS
·
Jun 02

Mirum Pharmaceuticals initiated with a Buy at Citi

TIPRANKS
·
Jun 02

Mirum announces new data from its rare liver disease programs at EASL

TIPRANKS
·
May 31

Mirum Pharmaceuticals Announces New Data From Rare Liver Disease Programs Presented at the Easl International Liver Congress 2026

THOMSON REUTERS
·
May 31

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 27

H.C. Wainwright Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 22

Mirum presents late-breaking Phase 2b VISTAS volixibat data in PSC pruritus at EASL 2026

Reuters
·
May 21